Incyte Q3 revenue $1.37B (+20% YoY); raises FY 2025 product revenue guidance to $4.23-4.32B

INCYTE CORP

2025-Q3 EPS reported $4.95 revenue$3,634,407,000

GAAP diluted EPS $2.11 vs $0.54 YoY; Non-GAAP diluted EPS $2.26 vs $1.07.
Jakafi net revenue $791M (+7%), Opzelura $188M (+35%), Niktimvo $46M (launch).
Raised FY 2025 Jakafi guidance to $3.05-3.075B, other oncology to $550-575M.
FDA approved Opzelura for pediatric atopic dermatitis (age 2+).
Plan to start registrational program for INCA33890 in MSS CRC in 2026; paused INCA034460, INCB57643, povorcitinib in CSU.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.